联系方式

简介

    梁宏，博士，教授。现任bat365在线平台登录入口省部共建药用资源化学与药物分子工程国家重点实验室/教育部重点实验室主任，博士生导师；曾任bat365在线平台登录入口校长（2002-2017），广西壮族自治区科协副主席，兼任南开大学、南京大学无机化学博士生导师和中南大学应用化学博士生导师（2001-2013）。在PNAS，Nat. Commun., J. Am. Chem. Soc., Angew. Chem. Int. Ed., Adv. Sci.，ACS Nano，J. Med. Chem., APSB, Small, Eur. J. Med. Chem., Anal. Chem., Inorg. Chem.和CCS Chem.,《中国科学》等国内外期刊发表SCI论文500余篇，并被SCI引用13800余次，H指数60；获授权中国发明专利80余项，欧洲发明专利1项；获得广西科学技术奖特别贡献奖、广西科技进步一等奖和广西自然科学一等奖等省级科技成果奖14项，广西优秀教学成果奖6项。

主要研究方向

1．中药活性成分金属药物化学生物学

2．新型抗肿瘤金属药物和蛋白质载药体系

3．诊疗一体化纳米医药材料

4．生命过程实时原位监测新方法

主要学术兼职

英国皇家化学会会士（FRSC）

中国化学会会士（FCCS）

中国化学会理事

中国化学会无机化学学科委员会委员

中国化学会化学生物学学科委员会委员

广西化学化工学会理事长（2001-2019）、荣誉理事长

国际期刊《Journal of Inorgnic Biochemistry》编委（2019-2012）

国际期刊《Journal of Natural Medicines Research》编委

中国化学会期刊《无机化学学报》编委

中国化学会期刊《化学教育》编委

讲授课程

生物无机化学

主要代表性论文： 

1.  Ke-BinHuang, Feng-Yang Wang, Yuan Lu, Liang-Mei Yang, Nian Long, Shan-Shan Wang,Zhiying Xie, Matthew Levinec, Taotao Zou*, Jonathan L. Sessler*, Hong Liang*. Cu(II) complex thatsynergisticallypotentiates cytotoxicity and an antitumor immune response bytargeting cellularredox homeostasis. PNAS, 2024, 121(24), e2404668121.

2.  XueyuMan , Wenjuan Li , Minghui Zhu , Shanhe Li , Gang Xu , Zhenlei Zhang , HongLiang*, Feng Yang*. Anticancer Tetranuclear Cu(I) Complex Catalyzes a ClickReaction to Synthesize a Chemotherapeutic Agent in situ to Achieve TargetedDual-Agent Combination Therapy for Cancer. Angew. Chem. Int. Ed., 2024 DOI: 10.1002/anie.202411846.

3.  PeijingXu, Changchun Wen, Cunji Gao*, Huihui Liu, Yingshu Li, Xiaolu Guo, Xing-CanShen*, Hong Liang*. Near-Infrared-II-ActivatableSelf-Assembled ManganesePorphyrin-Gold Heterostructures for PhotoacousticImaging-GuidedSonodynamic-Augmented Photothermal/Photodynamic Therapy. ACS Nano, 2024, 18,713−727.

4.  YuanLu, Shan-Shan Wang, Meng-Ya Li, Rong Liu, Meng-Fan Zhu, Liang-Mei Yang,Feng-Yang Wang, Ke-Bin Huang*, Hong Liang*. Cyclometalated iridium(III) complexbased on isoquinoline alkaloid synergistically elicits the ICD response and IDOinhibition via autophagy-dependent ferroptosis. Acta Pharm. Sin. B, 2024, DOI: 10.1016/j.apsb.2024.06.017.

5.  YulongBai, Jing Hua, Jingjin Zhao*, Shulong Wang, Mengjiao Huang, Yang Wang, YanniLuo, Shulin Zhao*, Hong Liang*. A Silver-Induced Absorption Red-ShiftedDual-Targeted Nanodiagnosis-Treatment Agent for NIR-II PhotoacousticImaging-Guided Photothermal and ROS Simultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy. Advance Science, 2023, 2306375.

6.  Qi-Yuan Yang+, Rui Ma+,Yun-Qiong Gu+, Xiao-Fang Xu, Zhen-Feng Chen*, Hong Liang*. Arene-Ruthenium(II)/Osmium(II) Complexes Potentiate the Anticancer Efficacy of Metformin via GlucoseMetabolism Reprogramming. Angew. Chem. Int. Ed., 2022, e202208570.

7.  Xiaolin XiongⅡ, Ke-BinHuangⅡ, Yuan WangⅡ, BeiCao, Yunli Luo, Huowen Chen, Yan Yang, Yan Long, MoyiLiu, Albert S. C. Chan, HongLiang*, Taotao Zou*. Target Profiling of anIridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. J. Am. Chem. Soc., 2022,144, 23, 10407–10416.

8.  Yan-Lei Ma*, Ji-Ping Yue*, Yao Zhang*, Chen-Zhang Shi*,Matt Odenwald, Wenguang G. Liang, Qing Wei, Ajay Goel, Xue-Wen Gou, JamieZhang, Shao-Yu Chen, Wei-Jen Tang, Jerrold R. Turner, Feng Yang, Hong Liang*, Huan-Long Qin, Xiao-YangWu. ACF7 regulates inflammatory colitis and intestinal wound response byorchestrating tight junction dynamics. Nat. Commun. 2017,8, 15375.

9.  Ji-Ping Yue, Yao Zhang, Wen-Guang G. Liang, Xue-Wen Gou,Philbert Lee, Han Liu, Wan-Qing Lyu, Wei-Jen Tang, Shao-Yu Chen, Feng Yang*, Hong Liang*, Xiao-Yang Wu*. InVivo Epidermal Migration Requires Focal Adhesion Targeting of ACF7. Nat.Commun. 2016, 7, 11692.

10.  Yi Gou,GuoJin Huang , Jinlong Li, Feng Yang*, Hong Liang*. Versatile delivery systemsfor non-platinum metal-based anticancer therapeutic agents, Coordin.Chem. Rev., 2021, 441, 213975.

11.  Wenjuan Li, Shanhe Li, Zhenlei Zhang, GangXu, Xueyu Man, Feng Yang*, Hong Liang*. Developing a Multitargeted AnticancerPalladium(II) Agent Based on the His-242 Residue in the IIA Subdomain of HumanSerum Albumin. J. Med. Chem., 2023, 66, 8564–8579.

12.  XingLu, Mei-Feng Wu, Jiang-Lun Wu, Hai-Qun Zhang, HongLiang*, Zhen-Feng Chen*. Platinum-Based Mcl‑1 Inhibitor Targeting Mitochondria Achieves Enhanced Antitumor Activity asa Single Agent or in Combination  withABT-199.J. Med. Chem., 2023, 66, 8705−8716.

13.  ZhenleiZhang†, Juzheng Zhang†, Tongfu Yang†, Shanhe Li, Gang Xu, Hong Liang*,Feng Yang*. Developing an Anticancer Platinum(II) Compound Based on theUniqueness of Human Serum Albumin. J. Med. Chem., 2023,66，5669−5684.

14.  XueyuMan§, Tongfu Yang§, Wenjuan Li, Shanhe Li, Gang Xu, Zhenlei Zhang, Hong Liang*,Feng Yang*. Developing a Gadolinium(III) Compound Based on Apoferritin forTargeted Magnetic Resonance Imaging and Dual-Modal Therapy of Cancer. J. Med. Chem., 2023,66, 7268−7279.

15.  TongfuYang, Zhenlei Zhang, Juzheng Zhang, Yanping Li, Wenjuan Li, Hong Liang*,Feng Yang*. Developing a Gallium(III) Agent Based on the Properties of theTumor Microenvironment and Lactoferrin: Achieving Two-Agent Co-delivery andMulti-targeted Combination Therapy of Cancer. J. Med. Chem., 2023,66，793−803.

16.  Shuang Kan, Rong Li, Yanhui Tan, Fang Yang, Shaohua Xu, Lingzhu Wang, Lijun Zhang, Xuchen Sun, Xuanming Chen, Yuting Yang, Wei Shu, Huaibin Wan, Zheng-Feng Chen, Hong Liang*, Ming Chen*. Latexin deficiency attenuates adipocyte differentiation and protects miceagainst obesity and metabolic disorders induced by high-fat diet. Cell Death & Disease,2022,13(2):175 .

17.  Wen-Ying Shen, Chun-Peng Jia, Li-YiLiao,Liu-Lin Chen, Cheng Hou, Yang-Han Liu, Hong Liang*, Zhen-Feng Chen*. Copper(II) Complexes ofHalogenated Quinoline Schiff Base Derivatives Enabled Cancer Therapy throughGlutathione-Assisted Chemodynamic Therapy and Inhibition of Autophagy Flux.  J. Med. Chem., 2022, 65,5134-5148.

18.  Ming Jiang, Yong Chu, Tongfu Yang, WenjuanLi, Zhenlei Zhang, Hongbin Sun, HongLiang*, Feng Yang*. Developing a Novel Indium(III) AgentBased on Liposomes to Overcome Cisplatin-Induced Resistance in Breast Cancer byMultitargeting the Tumor Microenvironment Components. J. Med. Chem.,2021,64, 14587–14602.

19.  ShulongWang, Jingjin Zhao, Liangliang Zhang*, Chaobang Zhang, Zhidong Qiu, Shulin Zhao*. Yong Huang, Hong Liang*. A Unique MultifunctionalNanoenzyme Tailored for Triggering Tumor Microenvironment Activated NIR-IIPhotoacoustic Imaging and Chemodynamic/Photothermal Combined Therapy. Adv. Healthcare Mater.,2021,2102073.

20.  Juzheng Zhang, Ming Jiang, Shanhe Li, ZhenleiZhang, Hongbin Sun, Feng Yang*, Hong Liang*. Developing a NovelAnticancer Gold(III) Agent to Integrate Chemotherapy and Immunotherapy. J. Med. Chem., 2021, 64, 6777–6791.

21.  Ju-Zheng Zhang, Zhen-Lei Zhang, MingJiang, Shan-He Li, Hao-Liang Yuan, Hong-Bin Sun, Feng Yang*, Hong Liang*. Developing a novelgold(III) agent to treat glioma based on the unique properties of apoferritinnanoparticles: inducing lethal autophagy and apoptosis，J. Med. Chem., 2020, 63, 13695–13708.

22.  Noor Shad Gul†, Taj-MalookKhan1†, Yan-Cheng Liu, Muhammad Iqbal Choudhary, Zhen-Feng Chen*, HongLiang*. Pd(II) and Rh(III) Complexes with Isoquinoline DerivativesInduced Mitochondria-Mediated Apoptotic and Autophagic Cell Death in HepG2Cells, CCS Chem., 2020, 2, 1626–1641.

23.  Xing Lu, Yan-Cheng Liu, Chris Orvig, HongLiang*, Zhen-Feng Chen*. Discovery of aCopper-Based Mcl‑1 Inhibitor as an Effffective Antitumor Agent, J. Med.Chem., 2020, 63, 9154–9167.

24.  Zhen-Lei Zhang, Ping Yu, Yi Gou,Ju-Zheng Zhang, Shan-He Li, Mei-Ling Cai, Hong-Bin Sun, Feng Yang*, HongLiang*. A novel brain-tumor-inhibitingcopper(II) compound based on HSA–cell penetrating peptide conjugate. J. Med. Chem., 2019, 62, 10630–13069.

25.  Ke-Bin Huang, Feng-Yang Wang, Xiao-Ming Tang, Hai-WenFeng, Zhen-Feng Chen*, Yan-Cheng Liu, You-Nian Liu, Hong Liang*. Organometallic Gold(III) Complexes Similar to TetrahydroisoquinolineInduce ER-Stress-Mediated Apoptosis and Pro-Death Autophagy in A549 CancerCells.J. Med. Chem.,2018,61, 3478-3490.

26.  Bang-Ping Jiang, Li Zhang, Xiao-Lu Guo,Xing-Can Shen*, Yan Wang, Yang Zhu,HongLiang*. Poly(N-phenylglycine)-Based Nanoparticles as HighlyEffective and Targeted Near-Infrared Photothermal Therapy/PhotodynamicTherapeutic Agents for Malignant Melanoma. Small,2017, 13, 1602496.

27.  Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Jie Zhou, Yu-Lan Li, Nan Li, Yan-Cheng Liu, Hong Liang*.Water-soluble ruthenium(II) complexes with chiral4-(2,3-Dihydroxypropyl)-formamide oxoaporphine (FOA): in vitro and in vivoanticancer activity by stabilization of G-Quadruplex DNA, inhibition oftelomerase activity, and induction of tumor cell apoptosis. J. Med. Chem. 2015, 58, 4771–4789.

28.  Zhen-FengChen*, Qi-Pin Qin, Jiao-Lan Qin, Yan-Cheng Liu, Ke-Bin Huang, Yu-Lan Li, TingMeng, Guo-Hai Zhang, Yan Peng, Xu-Jian Luo, Hong Liang*.  Stabilization of G-quadruplex DNA, inhibition oftelomerase activity, and tumor cell apoptosis by organoplatinum(II) complexeswith oxoisoaporphine. J. Med. Chem.,2015, 58, 2159–2179.

29.  Ming-HuaZeng*,Min-XiaYao, Hong Liang*, Wei-XiongZhang, Xiao-MingChen. A Single-Molecule-Magnetic, Cubane-Based, Triangular Co12Supercluster. Angew. Chem. Int. Ed., 2007, 46, 1832–1835.

近10年以来承担的主要科研项目

（1）973计划专项课题：基于中药活性成分金属抗肿瘤配合物研究和天然环肽类潜药的化学组装与活性评价（255万元）（2012-2015）

（2）国家自然科学基金-重点项目(21431001): 基于中药活性成分金属抗肿瘤配合物研究（360万元）(2015-2019)

（3）国家自然科学基金项目(22177022)：协同调控氧化(异)阿朴菲生物碱金属化合物的细胞毒活性与免疫激活响应研究 （60万元）(2022-2025)

（4）国家自然科学基金(21171043): 抗肿瘤先导植物药、金属基药物与人血清白蛋白相互作用研究（80万元） (2012-2015)

（5）教育部创新团队（学术带头人，排名第二）：天然活性物质的发现、结构改造与功能（450万元，2013-2016）（300万元，2017-2019滚动）

（6）广西院士后备人选培养工程项目：中药活性成分无机药物及其载运体系研究（1500万元） (2017-2022)

（7）广西重点研发计划项目：小龙虾细菌性疾病防治的广西中草药开发与关键技术研究（182万元）（2021-2023）

（8）广西自然科学基金项目（重点项目）：基于中药活性成分异喹啉类生物碱金属抗肿瘤配合物研究（100万元）（2013-2015）

（9）企业委托技术开发课题：珠海派锐尔新材料有限公司：对萘二甲酸的合成技术开发（250万元）（2023-2024）

主要荣誉称号 

国家“万人计划”（百千万工程）领军人才（2016年）

广西院士后备人选培养工程首批人选（2016年）

中国科协“西部开发突出贡献奖”（2008年）

全国优秀科技工作者（2005年）

教育部第三届“高校青年教师奖”（2002年）

中国青年科技奖（2001年）

国家有突出贡献的中青年专家（1999年）

广西优秀专业技术人员（1999年）

“广西十百千人才工程”第一层次人选（1998年）

国家“百千万人才工程”首批人选（1996年）

国务院政府特殊津贴（1996年）